Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25624526 | 0.86 | CYP2C19 (0.40) | CYP1A2CYP2D6CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL25626835 | 0.78 | — | — | |
| SCHEMBL25624610 | 0.78 | CYP3A4 (0.42) | CYP2D6ALDH1A1 | |
| SCHEMBL25624691 | 0.77 | PDE4B (0.34) | — | |
| SCHEMBL25627288 | 0.77 | — | — | |
| SCHEMBL25613052 | 0.75 | ALDH1A1 (0.44) | CYP1A2CYP2D6CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL25613054 | 0.71 | LTA4H (0.45) | CYP1A2CYP2D6CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL24005907 | 0.71 | LTA4H (0.35) | HTR6 | |
| SCHEMBL25624434 | 0.70 | MERTK (0.35) | — | |
| SCHEMBL25624362 | 0.68 | CDK1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | CYP1A2 2573/4885CYP2D6 3553/4885CYP2C19 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.